SkinBioTherapeutics (LSE:SBTX) has reported a strong set of full-year results for 2025, highlighted by a 284% surge in revenue to £4.6 million. Growth was fueled by rising direct sales and expanding royalty income tied to its AxisBiotix™ and Dermatonics product lines. During the year, the company completed a commercial partnership with Croda and launched Zenakine™ into the global cosmetics market, while also extending its retail reach through an exclusive distribution agreement with Superdrug Stores plc. The acquisitions of Bio-Tech Solutions and Dermatonics have strengthened both production capacity and financial performance, reinforcing SkinBioTherapeutics’ position within the growing skin health sector.
Despite these operational gains, the company continues to face meaningful financial pressures. Ongoing losses and cash burn weigh heavily on its stock assessment, and technical signals remain bearish. Although recent strategic achievements could deliver longer-term upside, the outlook is constrained until those developments translate into improved profitability and stronger financial stability.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life sciences company focused on improving skin health using its proprietary SkinBiotix® platform, developed by researchers at the University of Manchester. Its strategy spans five key pillars across skincare and the gut–skin axis, delivering products both directly to consumers and through retail partners such as Superdrug Stores plc. The company also maintains commercial collaborations, including its partnership with Croda plc.
Leave a Reply